| Document |
Document Title |
|
WO/2024/153018A1 |
The present disclosure relates to a crystal form of a spiro compound represented by formula (I), a preparation method therefor, and use thereof in treating diseases caused by coronavirus infection and/or small RNA virus infection.
|
|
WO/2024/153237A1 |
The present disclosure relates to compounds represented by formula I, and pharmaceutically acceptable salts, isotope-labeled substances or isomers thereof, which are IGF-1R kinase inhibitors and can be used for treating diseases such as ...
|
|
WO/2024/153025A1 |
The present application belongs to the field of pharmaceutical chemistry, discloses a series of substituted benzo-heptacyclic compounds and the use thereof, and specifically discloses a compound as represented by formula (I), a stereoiso...
|
|
WO/2024/153225A1 |
The disclosure is directed to novel ALPK1 inhibitors having the Formula (I), or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, a stable isotopic variant, a prodrug, or a crystal form thereof. The disclosure is also directe...
|
|
WO/2024/155021A1 |
The present invention provides: a novel compound which can improve the luminous efficiency, stability, and lifespan of an element; an organic electric element using same; and an electronic device thereof.
|
|
WO/2024/153724A1 |
The invention relates to novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5 and R6 are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2024/153775A1 |
The present invention relates to compounds of formula (I), (I) or pharmaceutically acceptable salts and/or solvates thereof, wherein m, n, R1, R2, R3, R4, R5, L, Ar1 and Ar2 are as defined in the claims, which are useful as inhibitors of...
|
|
WO/2024/155864A1 |
Provided herein are compounds having a structure of Formula (I) and pharmaceutically acceptable salts thereof which can act as modulators of serine/arginine-rich splicing factor protein kinase- 1 (SRPK1). Further disclosed herein are met...
|
|
WO/2024/153247A1 |
Provided in the present invention is a class of compounds. Specifically, provided in the present invention is a compound having a structure as shown in formula (I), or an optical isomer, pharmaceutically acceptable salt, prodrug, deutera...
|
|
WO/2024/152986A1 |
The present invention relates to a heteroaryl amino compound, a preparation method therefor, and use thereof, as well as a compound represented by formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a deuterate...
|
|
WO/2024/152247A1 |
Disclosed herein are certain bifunctional compounds that cause degradation of K-ras G12D via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by K-ras G12D, pharmaceutical compositions containi...
|
|
WO/2024/151833A1 |
The present disclosure provides compounds of Formula I: (l) (I), or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n,p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described...
|
|
WO/2024/149234A1 |
PARP7 inhibitors and uses thereof are disclosed.
|
|
WO/2024/110327A3 |
The present invention relates to substituted 4-amino-6-methylbenzaldehyde derivatives of the formula (I) as novel thermostable yellow methine dyes. The invention also relates to their use for dyeing plastics.
|
|
WO/2024/151346A1 |
The present application provides heteroaryl fluoroalkene compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
|
|
WO/2024/151919A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination and/or stereoisomers (e.g., enantiomers and diastereomers) of the compound) tha...
|
|
WO/2024/149231A1 |
Described herein, inter alia, are PARP7 inhibitors and uses thereof.
|
|
WO/2024/149728A1 |
The present disclosure relates to substituted anilines and heteroanilines and their use as TRPV4 antagonists. In some embodiments, the disclosure provides a compound of Formula (I): (I), or a pharmaceutically acceptable salt thereof, whe...
|
|
WO/2024/150991A1 |
The present invention provides: a novel compound that can improve the luminescence efficiency, stability, and lifespan of an element; an organic electric element using same; and an electronic device thereof.
|
|
WO/2024/149349A1 |
A compound as represented by formula (I), a stereoisomer, a deuterated substance, a solvate, a pharmaceutically acceptable salt or an eutectic crystal thereof, or a pharmaceutical composition containing same, and the use thereof as a com...
|
|
WO/2024/146923A1 |
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein B is an aryl or a five- or six-membered heteroaryl, and R1-R5, V, W, Y and Z may be various groups. The comp...
|
|
WO/2024/148049A1 |
The present invention provides compounds, compositions thereof, and methods of using the same to treat IRAK4-mediated disorder, disease, or condition in a patient.
|
|
WO/2024/120505A9 |
The present invention relates to a fused ring derivative, a preparation method therefor, intermediates thereof, and use thereof. Particularly, the present invention relates to a compound represented by general formula (I), a preparation ...
|
|
WO/2024/148041A1 |
The present invention provides compounds, compositions thereof, and methods of using the same to treat a STAT3-mediated disorder, disease, or condition in a patient. The present invention provides 6-oxodecahydropyrrolo[1,2-a][1,5]diazoci...
|
|
WO/2024/147009A1 |
One aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, X is NH and Y is CO ring C is a 6-membered heteroaryl or aryl group, or a partially or fully unsaturated 6-member...
|
|
WO/2024/140700A1 |
The present invention provides a benzothiazole compound as shown in formula (I). The present invention further provides a synthesis method for the compound, and synthesis for an important intermediate in the preparation method. The benzo...
|
|
WO/2024/140850A1 |
The present invention relates to a protein tyrosine kinase inhibitor and a use thereof in prevention and/or treatment of protein tyrosine kinase-mediated hyperproliferative diseases, such as ocular diseases and malignant tumors accompani...
|
|
WO/2024/140653A1 |
The present invention belongs to the field of pharmaceutical chemistry, relates to a compound serving as a CDK12/13 inhibitor and to application of the compound, and specifically provides a compound shown in formula (I), or an isomer, ph...
|
|
WO/2024/145483A1 |
Disclosed herein are compounds that inhibit RNA modifying enzymes, such as METTL3, and thus can be used for treating and/or preventing diseases, such as cancers. Also disclosed herein are methods for making and using the disclosed compou...
|
|
WO/2024/140637A1 |
The present disclosure relates to a compound of formula (I) or a salt, enantiomer, stereoisomer, solvate or polymorph thereof, and a use thereof. The present disclosure further relates to a pharmaceutical composition comprising the compo...
|
|
WO/2024/141015A1 |
Provided are compounds, methods for modulating or inhibiting PTPN1/2 and pharmaceutical compositions comprising such compounds and methods of treatment using such compounds.
|
|
WO/2024/145662A1 |
Provided herein are compounds, compositions and methods for the treatment of a disease characterized by DUX4 misexpression. In certain embodiments, the inventive compounds and compositions can be administered either alone or in combinati...
|
|
WO/2024/140671A1 |
The present invention relates to a fused tricyclic derivative, a pharmaceutical composition comprising same, and an application thereof. Specifically, the present invention provides a compound shown in formula (I) or a pharmaceutically a...
|
|
WO/2024/140923A1 |
Provided in the present invention is a compound used as a PRMT5-MTA inhibitor, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof. Also provided in the...
|
|
WO/2024/141004A1 |
Provided herein are novel compounds as inhibitors of macrophage migration inhibitory factor (MIF) pharmaceutical compositions comprising the compounds provided herein; as well as uses and methods for treating a disease mediated by MIF by...
|
|
WO/2024/140970A1 |
Disclosed in the present invention are a bicyclic compound and a use thereof in drugs, particularly relating to a novel bicyclic compound and a pharmaceutical composition containing the compound. The invention also relates to a preparati...
|
|
WO/2024/139454A1 |
The present invention relates to a crystal form I of ropivacaine/meloxicam salt monohydrate, a pharmaceutical composition, a preparation method therefor and the use thereof. The X-ray powder diffraction pattern of the crystal form I of r...
|
|
WO/2024/140638A1 |
The present disclosure relates to the technical field of molecular glue degradation agents, and in particular to a compound of formula I based on a sulfur/oxygen substituted glutarimide-based isoindolinone skeleton and a use thereof. The...
|
|
WO/2024/141757A1 |
Disclosed are compounds, compositions and methods for treating disease, syndromes, conditions and disorders that are affected by the modulation of LSD1. Such compounds are represented by formula (I) wherein the variables are defined herein.
|
|
WO/2024/137813A1 |
The present invention provides novel sulfonamide compounds that are modulators of POLγ for treating various diseases such as cancer and others associated with metabolic disorders and mitochondrial dysfunction.
|
|
WO/2024/137981A1 |
Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein Ring A, Ring B, L, RB, Rc, n, and p are as defined herein. Also provided are pharmaceutically acceptable compositions comprising a compound of ...
|
|
WO/2024/131882A1 |
Disclosed in the present invention are a salt form and a crystal form of a pyridine multi-substituted compound and a preparation method therefor. Specifically disclosed is the use of a crystal form of a compound of formula (I) and a prep...
|
|
WO/2024/130344A1 |
The present invention relates to methods and uses of preventing or treating cancer The method or use may comprise administration of a cancer therapy together with a compound of Formula (I). In the compound of Formula (I) A is a substitut...
|
|
WO/2024/133499A1 |
The invention relates to glycine derivatives with P2X4 receptor-blocking activity for the treatment of pain, inflammation, cancer, and other P2X4 receptor-related diseases.
|
|
WO/2024/131948A1 |
The present invention belongs to the field of drug synthesis. Specifically, disclosed is a method for preparing a P2X3 inhibitor, i.e., 2-fluoro-5-(((2S,3R)-3-hydroxybutan-2-yl)oxy)-3(5-methylthia
zol-2-yl)-N-((R)-1-(2-(trifluoromethyl)p...
|
|
WO/2024/135443A1 |
The present invention addresses the problem of providing a photoelectric conversion element that has excellent quantum efficiency and excellent suitability for manufacturing. The present invention also addresses the problem of providing ...
|
|
WO/2024/137506A1 |
In various aspects and embodiments provided are compositions and methods for identifying subjects in need of improving cognition and/or treating a neurodegenerative disease in a subject and treating such subject. More specifically, the d...
|
|
WO/2024/137742A1 |
Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as FGFR3 degraders).
|
|
WO/2024/137607A1 |
The present disclosure relates to compounds of Formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein Ring A, R1, R2, R3, R4, and m are described herein, methods of preparation, methods of treatment, and pharmaceutical c...
|
|
WO/2024/137724A1 |
Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined here and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphata...
|
